Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

Core Insights - Sutro Biopharma, Inc. is a clinical-stage oncology company focused on developing site-specific and novel-format antibody drug conjugates (ADCs) [1][3] - The company will present at the TD Cowen 45th Annual Health Care Conference from March 3-5, 2025, in Boston, MA [1] - Sutro's technology, including cell-free XpressCF, aims to enhance patient benefits and experiences through precisely designed cancer therapeutics [3] Company Overview - Sutro Biopharma is headquartered in South San Francisco and is dedicated to the discovery and development of cancer therapeutics [3] - The company has multiple clinical-stage candidates, including luveltamab tazevibulin (luvelta), which is a registrational-stage ADC targeting folate receptor alpha (FolRα) [3] - Sutro's robust pipeline and high-value collaborations validate its continuous product innovation [3] Investor Relations - The presentation at the conference will be accessible through the company's Investor Relations section on its website, with an archived replay available for at least 30 days post-event [2]